Search

for
Search:

GlossaryGoserelin (Zoladex)

reduces sex hormone production to treat hormone-sensitive cancers

Goserelin, also known by the brand name Zoladex, is a type of medication called a gonadotropin-releasing hormone (GnRH) agonist. It is used to treat hormone-sensitive cancers such as prostate cancer in men and breast cancer in premenopausal women, as well as certain benign gynecological conditions like endometriosis. Goserelin works by reducing the production of sex hormones (testosterone and estrogen), which can help slow the growth of hormone-dependent tumors.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 21 results

research Effect of the Gonadotrophin-Releasing Hormone Analogue, Goserelin, and Estradiol Replacement on Sebum Excretion Rates and Hair Size in Mildly Hirsute Women

4 citations, January 1991 in “Journal of dermatological treatment”

Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.

research Slow Progress in Prostate Cancer

February 2007 in “BJUI”

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

research Triple Hormonal Blockade (ADT3): A Patient’s Perspective

January 2019 in “Oncogen”

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

research Is Dehydroepiandrosterone a Hormone?

403 citations, November 2005 in “Journal of Endocrinology”

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content

research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content

82 citations, February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

View more "zoladex" in research →

Community Join

0 / 0 results

— no results